PAX
pet allergy xplorer

Evidence-based drug withdrawal times for allergen-specific IgE serological and intradermal testing

Update: April 2024

Product	Dosage	Optimal Withdrawal Times			
		IgE serology	Ref.	Intradermal Test	Ref.
H1R antihistamines (hydroxyzine, cetirizine)	standard	likely none	a	7 days	1
Oral glucocorticoids (prednisolone, methylprednisolone)	anti-allergic	none	1, b	7 days	1
Long-acting injectable glucocorticoids (methylprednisolone acetate)	approved	< 28 days	1	28 days	1
Topical glucorticoids (hydrocortisone aceponate)	approved	likely none	1, c	14 days	1, 2
Otic glucorticoids (hydrocortisone aceponate)	approved	likely none	1, c	14 days	1
Essential fatty acids (Pet's Relief Atopi-3; fish oil)	standard	none	1	none	1
Oral ciclosporin	approved	none	1, d	none	1, d
Topical tacrolimus	standard	none	1	none	1
Oral oclacitinib	approved	none	3-5, e	none	3-5, e
Injectable lokivetmab	approved	none	6, f	none	6

(a) Although not tested, there is no mechanism by which H1R antihistamines could affect the results of an allergen-specific IgE serology.

(b) No studies have been conducted on the withdrawal times needed for dosages higher than 1 mg/kg/day or an administration longer than 8 weeks.

(c) No studies have been conducted on the effect of a topical and otic glucocorticoid for cutaneous use on allergen-specific IgE serology. The recommendation herein is derived from the optimal withdrawal time for prednisolone.

(d) No studies have been conducted on the withdrawal times needed for dosages higher than 5 mg/kg/day or an administration longer than 8 weeks.

(e) No studies have been conducted on the withdrawal times needed for dosages higher than 0,4-0,6 mg/kg/day or an administration longer than 30 days.

(f) No studies have been conducted on the withdrawal times needed for dosages higher than 3.3 mg/kg or more than one injection.

References:

1. Olivry T, Saridomichelakis M for the ICADA: Evidence-based guidelines for anti-allergic drug withdrawal times before allergen-specific intradermal and IgE serological tests in dogs. Vet Dermatol 2013; 24: 225-e49
2. Bizikova P, Linder KE, Paps JS, Olivry T: Effect of a novel topical diester glucocorticoid spray on immediate- and late-phase cutaneous allergic reactions in Maltese–beagle atopic dogs: a placebo-controlled study. Vet Dermatol 2010; 21: 70-79.
3. Aleo MM, Messamore J, Nieto BA, Fleck TJ, Humphrey WR, Coscarelli, EM, Mahabir SP, McCall RB, Gonzales AJ: Lack of Interference of Oclacitinib with the results of intradermal testing or allergen-specific IgE serology in Dermatophagoides farinae-sensitized beagle dogs. Vet Immunol Immunopathol 2023; 256: 110537.
4. Clear V, Petersen A, Rosser EJ, Ruggiero V. Investigation of the effects of 30 day administration of oclacitinib on intradermal and allergen-specific IgE serology testing in atopic dogs (abstract). Vet Dermatol 2015; 26:133-159.
5. Baretta LT, do Espirito Santo Cunha V, Deon Figueiredo C; Guimarães Gerardi D: A randomized, double-blinded trial to assess the effect of oclacitinib and prednisolone on intradermal allergen and prick tests in dogs with atopic dermatitis. Vet Dermatol 2024; 35:71-80.
6. Aleo M, Mahabir S, Bainbridge G, Martinon O, Dunham S. Comparison of effects of lokivetmab versus prednisolone on intradermal testing in Dermatophagoides farinae sensitized beagles (abstract, P38). Vet Dermatol 2016; 27: 79.